Faculty
A. Eden Evins, MD, MPH
a_eden_evins@hms.harvard.edu
Eden Evins, MD, is an Assistant Professor of Psychiatry at Harvard Medical School and Director of the Addiction Research Program of the Massachusetts General Hospital. She is a member of the Schizophrenia Program and the Depression Clinical and Research Program of the Massachusetts General Hospital where she directs smoking cessation studies and clinical programs.
Dr. Evins earned her undergraduate degree at University of Virginia in Charlottesville, VA, and her medical degree at the Medical University of South Carolina in Charleston. After graduating, she completed her residency in adult psychiatry at the Massachusetts Mental Health Center and Longwood Psychiatry Residency Training Program in Boston, where she was also Chief Resident. She conducted a fellowship in molecular biology at the Mailman Research Center of McLean Hospital and a second fellowship in schizophrenia research at the Massachusetts General Hospital with Dr. Donald Goff. She received a Masters in Public Health in Clinical Effectiveness at the Harvard School of Public Health.
Dr. Evins’ research interests include pharmacotherapy for negative symptoms in schizophrenia, treatment for cognitive dysfunction in schizophrenia, and treatment of nicotine addiction in patients with schizophrenia and depression. She has authored book chapters, reviews and articles that have been published in prestigious scientific journals, such as American Journal of Psychiatry, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of Neural Transmission, and Biological Psychiatry.
Dr. Evins has been the recipient of the NIMH New Clinical Drug Evaluation Unit Young Investigator Award, the Massachusetts Department of Public Health Tobacco Control Program Young Investigator Award, and has twice been the recipient of the National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award. Dr. Evins is currently funded by a career development award from the National Institutes of Drug Abuse (NIDA) for her work on nicotine use in schizophrenia, by the Stanley Foundation to study the effect of nicotinic agonists on cognitive function in schizophrenia, and by a grant from NIDA for the study of novel compounds for smoking cessation in the general population.
« Previous Page
| 
